Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Financial Results:
Wockhardt Ltd reported Revenues for Q1FY24 of ₹644.00 Crores up from ₹595.00 Crore year on year, a rise of 8.24%.
Total Expenses for Q1FY24 of ₹762.00 Crores up from ₹748.00 Crores year on year, a rise of 1.87%.
Consolidated Net Profit of -₹136.00 Crores from -₹75.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹9.30, from -₹4.65 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.